Senseonics Holdings Inc (NYSE American: SENS) is a medical device company that develops and commercializes implantable continuous glucose monitoring (CGM) systems for people with diabetes. Revenue comes from sales of the Eversense CGM system and related components and supplies, sold through a network of healthcare professionals via a consignment program and through its own patient services subsidiary, Eon Care. Senseonics previously relied on Ascensia as its third-party commercial partner in the United States and select international markets; as of the FY2025 10-K filing period, the company was transitioning commercial responsibility for Eversense back from Ascensia. Manufacturing is fully outsourced to contract manufacturers across North America and Europe. The company established Eon Care Services, LLC and Eon Management Services, LLC in 2024 to provide Eversense insertion and training services directly to patients, with the full network transition completed in Q2 FY2025. CEO Tim Goodnow leads the company alongside CFO Rick Sullivan and COO Mukul Jain.

Revenue model

Transactional sales of the Eversense implantable CGM system and related components and supplies through a consignment program with healthcare professionals and through Eon Care, the company's own insertion and patient services network. Reimbursement depends on coverage from private insurers, government payors, and national healthcare systems.

Products and services

Eversense implantable continuous glucose monitoring (CGM) system, including the sensor, transmitter, and related components and supplies. Eon Care provides Eversense insertion and training services to patients.

Customers and end markets

People with diabetes requiring continuous glucose monitoring. End markets include the United States and international markets, primarily European territories. Payers include private health insurance plans, government healthcare programs, and national healthcare systems.

Value-chain role

Medical device developer and commercial-stage manufacturer (via outsourced contract manufacturers) of implantable CGM systems. Senseonics handles product development, regulatory approval, and increasingly direct commercialization through Eon Care, with manufacturing outsourced to third-party contract manufacturers in North America and Europe.

Geographic exposure

United States and European territories. International coverage and payment contracts for Eversense in European markets were historically managed by Ascensia; Senseonics was in the process of acquiring those contracts as of the filing date (10-K filed 2026-03-02).

Source: SEC 10-K, filed 2026-03-02

Industry: Industrial Instruments For Measurement, Display, and Control Peers: Abbott Laboratories CUTERA INC AngioDynamics Inc Artivion Inc Cardiovascular Systems Inc Outset Medical Inc Inogen Inc Mesa Laboratories Inc ViewRay, Inc. SI-BONE Inc